SAN DIEGO, Dec. 8, 2021 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to
adjourn, without conducting any business, its 2021 special meeting
of stockholders (the "Special Meeting") scheduled to occur at
8:00 a.m. PST on December 8, 2021, and reconvene at 8:00 a.m. PST on December
15, 2021, to vote on the proposal described in the proxy
statement filed with the Securities and Exchange Commission (the
"SEC") on November 9, 2021.
The Special Meeting will still be held its corporate offices
located at 12400 High Bluff Drive, Suite 600, San Diego, California 92130. The Company does
not intend to change the record date for the Special Meeting. Only
stockholders of record at the close of business on November 5, 2021, are entitled to vote at the
reconvened Special Meeting.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to the
proposal set forth in its proxy statement. Proxies previously
submitted in respect of the Special Meeting will be voted at the
adjourned meeting unless properly revoked.
No changes have been made to the proposal to be voted on by
stockholders at the Annual Meeting. The Company's proxy statement
and any other materials filed by the Company with the SEC remain
unchanged and can be obtained free of charge through Evofem's
website at https://evofem.investorroom.com/SEC-filings and at
https://www.sec.gov/.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is developing and commercializing innovative
products and product candidates to address unmet needs in women's
sexual and reproductive health, including hormone-free,
woman-controlled contraception and protection from certain sexually
transmitted infections (chlamydia and gonorrhea). The Company's
first FDA-approved product, Phexxi® (lactic acid, citric acid and
potassium bitartrate), is a hormone-free, on-demand prescription
contraceptive vaginal gel. It comes in a box of 12 pre-filled
applicators and is applied 0-60 minutes before each act of sex.
Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact:
Ellen
Thomas
718-490-3248
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-adjourn-special-meeting-of-stockholders-on-december-8-2021-301439947.html
SOURCE Evofem Biosciences, Inc.